<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11</volume><submitter>Piesche M</submitter><funding>Aarhus Universitets Forskningsfond</funding><funding>Deutsche Forschungsgemeinschaft</funding><funding>Else Kröner-Fresenius-Stiftung</funding><pubmed_abstract>Nitro fatty acids (NFAs) are endogenously generated lipid mediators deriving from reactions of unsaturated electrophilic fatty acids with reactive nitrogen species. Furthermore, Mediterranean diets can be a source of NFA. These highly electrophilic fatty acids can undergo Michael addition reaction with cysteine residues, leading to post-translational modifications (PTM) of selected regulatory proteins. Such modifications are capable of changing target protein function during cell signaling or in biosynthetic pathways. NFA target proteins include the peroxisome proliferator-activated receptor &lt;i>γ&lt;/i> (PPAR-&lt;i>γ&lt;/i>), the pro-inflammatory and tumorigenic nuclear factor-κB (NF-κB) signaling pathway, the pro-inflammatory 5-lipoxygenases (5-LO) biosynthesis pathway as well as soluble epoxide h</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>1297</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7495092</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer.</pubmed_title><pmcid>PMC7495092</pmcid><pubmed_authors>Matrone C</pubmed_authors><pubmed_authors>Hellmuth N</pubmed_authors><pubmed_authors>Maucher IV</pubmed_authors><pubmed_authors>Heinicke U</pubmed_authors><pubmed_authors>Awad O</pubmed_authors><pubmed_authors>Zacharowski KD</pubmed_authors><pubmed_authors>Comerma Steffensen SG</pubmed_authors><pubmed_authors>Kuhn B</pubmed_authors><pubmed_authors>Piesche M</pubmed_authors><pubmed_authors>Brat C</pubmed_authors><pubmed_authors>Maier TJ</pubmed_authors><pubmed_authors>Steinhilber D</pubmed_authors><pubmed_authors>Roos J</pubmed_authors><pubmed_authors>Fettel J</pubmed_authors><pubmed_authors>Manolikakes G</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer.</name><description>Nitro fatty acids (NFAs) are endogenously generated lipid mediators deriving from reactions of unsaturated electrophilic fatty acids with reactive nitrogen species. Furthermore, Mediterranean diets can be a source of NFA. These highly electrophilic fatty acids can undergo Michael addition reaction with cysteine residues, leading to post-translational modifications (PTM) of selected regulatory proteins. Such modifications are capable of changing target protein function during cell signaling or in biosynthetic pathways. NFA target proteins include the peroxisome proliferator-activated receptor &lt;i>γ&lt;/i> (PPAR-&lt;i>γ&lt;/i>), the pro-inflammatory and tumorigenic nuclear factor-κB (NF-κB) signaling pathway, the pro-inflammatory 5-lipoxygenases (5-LO) biosynthesis pathway as well as soluble epoxide h</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-05-29T19:02:36.537Z</modification><creation>2020-11-19T16:58:17Z</creation></dates><accession>S-EPMC7495092</accession><cross_references><pubmed>33013366</pubmed><doi>10.3389/fphar.2020.01297</doi></cross_references></HashMap>